Kamada Ltd. (KMDA)
USD 5.76
(-1.37%)
USD 5.76
(-1.37%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 7.43 Million USD | -50.87% |
| 2022 | 15.14 Million USD | -26.39% |
| 2021 | 20.56 Million USD | 466.74% |
| 2020 | 3.62 Million USD | -14.37% |
| 2019 | 4.23 Million USD | 491.9% |
| 2018 | 716 Thousand USD | -47.74% |
| 2017 | 1.37 Million USD | 0.44% |
| 2016 | 1.36 Million USD | 803.31% |
| 2015 | 151 Thousand USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 7.49 Million USD | -60.0% |
| 2012 | 18.74 Million USD | -16.75% |
| 2011 | 22.51 Million USD | -2.76% |
| 2010 | 23.15 Million USD | 10.76% |
| 2009 | 20.9 Million USD | 10.82% |
| 2008 | 18.86 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 7.27 Million USD | 0.0% |
| 2024 Q2 | 7.06 Million USD | 0.0% |
| 2023 Q2 | 15.71 Million USD | -6.71% |
| 2023 FY | 7.43 Million USD | -50.87% |
| 2023 Q4 | 7.43 Million USD | 57.68% |
| 2023 Q1 | 16.84 Million USD | 11.25% |
| 2023 Q3 | 4.71 Million USD | -69.98% |
| 2022 Q3 | 16.48 Million USD | -6.73% |
| 2022 Q1 | 19.35 Million USD | -5.91% |
| 2022 Q2 | 17.67 Million USD | -8.66% |
| 2022 FY | 15.14 Million USD | -26.39% |
| 2022 Q4 | 15.14 Million USD | -8.18% |
| 2021 Q3 | 3.28 Million USD | -3.61% |
| 2021 Q1 | 3.43 Million USD | -5.29% |
| 2021 FY | 20.56 Million USD | 466.74% |
| 2021 Q2 | 3.4 Million USD | -0.9% |
| 2021 Q4 | 20.56 Million USD | 526.47% |
| 2020 Q3 | 3.63 Million USD | -3.45% |
| 2020 Q2 | 3.76 Million USD | -0.89% |
| 2020 Q1 | 3.8 Million USD | -10.31% |
| 2020 Q4 | 3.62 Million USD | -0.22% |
| 2020 FY | 3.62 Million USD | -14.37% |
| 2019 FY | 4.23 Million USD | 491.9% |
| 2019 Q1 | 4.62 Million USD | 546.23% |
| 2019 Q2 | 4.47 Million USD | -3.39% |
| 2019 Q3 | 4.51 Million USD | 0.96% |
| 2019 Q4 | 4.23 Million USD | -6.09% |
| 2018 Q4 | 716 Thousand USD | -18.64% |
| 2018 FY | 716 Thousand USD | -47.74% |
| 2018 Q3 | 880 Thousand USD | -13.47% |
| 2018 Q2 | 1.01 Million USD | -15.32% |
| 2018 Q1 | 1.2 Million USD | -12.34% |
| 2017 Q3 | 1.5 Million USD | 4.75% |
| 2017 Q2 | 1.43 Million USD | 7.74% |
| 2017 Q1 | 1.33 Million USD | -2.49% |
| 2017 FY | 1.37 Million USD | 0.44% |
| 2017 Q4 | 1.37 Million USD | -8.73% |
| 2016 Q2 | 1.53 Million USD | 114.66% |
| 2016 Q3 | 1.5 Million USD | -2.28% |
| 2016 Q4 | 1.36 Million USD | -9.19% |
| 2016 Q1 | 716 Thousand USD | 374.17% |
| 2016 FY | 1.36 Million USD | 803.31% |
| 2015 Q4 | 151 Thousand USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | 151 Thousand USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q3 | 7.71 Million USD | -4.08% |
| 2014 Q1 | 7.68 Million USD | 2.51% |
| 2014 Q2 | 8.03 Million USD | 4.59% |
| 2014 FY | - USD | -100.0% |
| 2014 Q4 | - USD | -100.0% |
| 2013 FY | 7.49 Million USD | -60.0% |
| 2013 Q3 | 20.65 Million USD | 3.63% |
| 2013 Q2 | 19.93 Million USD | 2.19% |
| 2013 Q1 | 19.5 Million USD | 4.03% |
| 2013 Q4 | 7.49 Million USD | -63.7% |
| 2012 FY | 18.74 Million USD | -16.75% |
| 2012 Q3 | 22.71 Million USD | 0.0% |
| 2012 Q4 | 18.74 Million USD | -17.48% |
| 2011 FY | 22.51 Million USD | -2.76% |
| 2010 FY | 23.15 Million USD | 10.76% |
| 2009 FY | 20.9 Million USD | 10.82% |
| 2008 FY | 18.86 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Journey Medical Corporation | 14.62 Million USD | 49.131% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 97.598% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 91.833% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 98.552% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -1279.873% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -1279.873% |
| SCYNEXIS, Inc. | 12.15 Million USD | 38.827% |
| Safety Shot Inc | 304.9 Thousand USD | -2339.432% |
| Alpha Teknova, Inc. | 13.25 Million USD | 43.868% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 98.482% |
| Bright Green Corporation | 201.78 Thousand USD | -3586.138% |
| Dynavax Technologies Corporation | 252.41 Million USD | 97.053% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 98.517% |
| Cosmos Health Inc. | 3.03 Million USD | -145.047% |
| PainReform Ltd. | 30 Thousand USD | -24693.333% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -6250.263% |
| Embecta Corp. | 1.62 Billion USD | 99.542% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | 44.184% |
| Procaps Group, S.A. | 28.41 Million USD | 73.819% |
| Theratechnologies Inc. | 51.26 Million USD | 85.49% |
| Harrow Health, Inc. | 183.17 Million USD | 95.939% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -8449.425% |
| Biofrontera Inc. | 804 Thousand USD | -825.124% |
| DURECT Corporation | 2.7 Million USD | -175.278% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 77.594% |
| Cronos Group Inc. | 1.55 Million USD | -377.101% |
| OptiNose, Inc. | 611 Thousand USD | -1117.349% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 98.507% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 78.245% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -1534.725% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 87.755% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 41.819% |
| Radius Health, Inc. | 339.66 Million USD | 97.81% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | 27.491% |
| Phibro Animal Health Corporation | 458.28 Million USD | 98.377% |
| Procaps Group S.A. | 28.41 Million USD | 73.819% |
| Alvotech | 1.02 Billion USD | 99.276% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -13.87% |
| Viatris Inc. | 16.18 Billion USD | 99.954% |
| Rockwell Medical, Inc. | 8.29 Million USD | 10.31% |
| Aytu BioPharma, Inc. | 10.87 Million USD | 31.617% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -2113.75% |
| Tilray Brands, Inc. | 287.93 Million USD | 97.417% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 93.828% |
| Shineco, Inc. | 10.01 Million USD | 25.749% |
| PetIQ, Inc. | 437.82 Million USD | 98.301% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -3441.905% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 97.12% |
| Alimera Sciences, Inc. | 64.48 Million USD | 88.466% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | 80.688% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -5406.0% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -8.467% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -933.056% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -32981.302% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | 77.295% |
| Hempacco Co., Inc. | 5.93 Million USD | -25.409% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 99.276% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 86.769% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 98.793% |
| Currenc Group, Inc. | 2.5 Million USD | -196.692% |
| Indivior PLC | 235.66 Million USD | 96.844% |
| Evoke Pharma, Inc. | 5 Million USD | -48.76% |
| Flora Growth Corp. | 942 Thousand USD | -689.597% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -32981.302% |
| Evolus, Inc. | 120.35 Million USD | 93.82% |
| HUTCHMED (China) Limited | 48.18 Million USD | 84.565% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 98.738% |
| Akanda Corp. | 2.49 Million USD | -197.859% |